Nuo Therapeutics, Inc. (AURX)

OTCMKTS · Delayed Price · Currency is USD
0.9900
-0.1170 (-10.57%)
May 26, 2026, 2:11 PM EST
Market Cap47.92M -27.3%
Revenue (ttm)4.13M +155.8%
Net Income-2.38M
EPS-0.05
Shares Out 48.40M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Open1.0000
Previous Close1.1070
Day's Range0.9900 - 1.0000
52-Week Range0.9359 - 3.2300
Beta-831.10
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Nuo Therapeutics

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 10
Stock Exchange OTCMKTS
Ticker Symbol AURX
Full Company Profile

Financial Performance

In 2025, Nuo Therapeutics's revenue was $3.31 million, an increase of 142.72% compared to the previous year's $1.37 million. Losses were -$2.51 million, 8.11% more than in 2024.

Financial Statements

News

Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic...

12 days ago - GlobeNewsWire

Nuo Therapeutics initiated with a Buy at Roth Capital

Roth Capital analyst Kyle Bauser initiated coverage of Nuo Therapeutics (AURX) with a Buy rating and $3 price target The firm sees the company’s technology as positioned for “significant growth”…

5 months ago - TheFly

Nuo Therapeutics management to meet virtually with Roth Capital

Virtual Meeting to be held on December 4 hosted by Roth Capital.

6 months ago - TheFly

Nuo Therapeutics files $14M common stock offering

16:49 EDT Nuo Therapeutics (AURX) files $14M common stock offering

1 year ago - TheFly

Nuo Therapeutics enters Centrio distribution pact with Smith & Nephew

Nuo Therapeutics (AURX) announced it has entered into an exclusive private label distribution agreement with Smith & Nephew (SNN). Under the agreement, Smith+Nephew will market and sell Centrio Platel...

1 year ago - TheFly

Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging...

1 year ago - GlobeNewsWire

Nuo Therapeutics, PAM Health partner to advance access to wound healing therapy

A multi-year exclusive agreement between PAM Health and Nuo Therapeutics (AURX) means Nuo’s Aurix System will serve as the sole platelet-rich plasma wound care therapy across all of PAM Health’s…

1 year ago - TheFly

Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chro...

1 year ago - GlobeNewsWire

Nuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange

HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging ...

3 years ago - GlobeNewsWire

Nuo Therapeutics’ Aurix System added to WCA formulary

Nuo Therapeutics announces that Wound Care Advantage, WCA, the nation’s leading wound care consulting firm has added the Aurix System to its formulary. Wound Care Advantage has established a large…

3 years ago - TheFly

Nuo Therapeutics' Aurix® System Added To Wound Care Formulary Of Wound Care Advantage

HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging ...

3 years ago - GlobeNewsWire

Nuo Therapeutics Provides Corporate and Business Update

Broad equity incentive agreement established with Pacific Medical, Inc. including initial equity purchase

4 years ago - GlobeNewsWire